Mishra Rakhi, Sharma Suresh K, Verma Rajni, Kangra Priyanka, Dahiya Preeti, Kumari Preeti, Sahu Priya, Bhakar Priyanka, Kumawat Reena, Kaur Ravinder, Kaur Ravinder, Kant Ravi
College of Nursing, All India Institute of Medical Sciences, Uttarakhand 249203, Rishikesh, India.
Department of Medicine, All India Institute of Medical Sciences, Uttarakhand 249203, Rishikesh, India.
World J Diabetes. 2021 Oct 15;12(10):1740-1749. doi: 10.4239/wjd.v12.i10.1740.
Diabetes mellitus (DM) is a progressively increasing metabolic disorder and a significant public health burden that demands immediate global attention. However, there is a paucity of data about adherence to antidiabetic drugs among patients with type-2 (T2)DM in Uttarakhand, India. Outpatient research reported that more than 50% of patients do not adhere to the correct administration and appropriate medicine dosage. It has been reported that patients with chronic diseases who adhere to treatment may experience improvement in quality of life (QoL) and vice versa.
To assess the adherence to antidiabetic medication and QoL among patients with T2DM.
This cross-sectional descriptive study was conducted at a tertiary care hospital in Uttarakhand, India. The Medication Adherence Rating Scale and World Health Organization QoL-BREF scale were used to assess medication adherence and QoL.
Two hundred seventy-seven patients suffering from T2DM participated in the study. Their mean age was 50.80 (± 10.6) years, 155 (56%) had a poor adherence level and 122 (44%) had a good adherence level to antidiabetic medications. After adjusting for sociodemographic factors, multiple linear regression analysis found patients who were adherent to antidiabetic medications had significantly higher mean overall perception of QoL and overall perception of health, with beta scores of 0.36 and 0.34, respectively (both = 0.000) points compared with nonadherent patients.
There was an association between medication adherence and QoL in patients with T2DM. Hence, there is a need to plan awareness and counseling programs followed by regular follow-up to motivate patient adherence to recommended treatment and lifestyle regimens.
糖尿病(DM)是一种日益普遍的代谢紊乱疾病,也是一项重大的公共卫生负担,需要全球立即予以关注。然而,关于印度北阿坎德邦2型糖尿病(T2DM)患者对抗糖尿病药物的依从性的数据却很匮乏。门诊研究报告称,超过50%的患者未坚持正确用药和适当的药物剂量。据报道,坚持治疗的慢性病患者生活质量(QoL)可能会有所改善,反之亦然。
评估T2DM患者对抗糖尿病药物的依从性和生活质量。
这项横断面描述性研究在印度北阿坎德邦的一家三级护理医院进行。采用药物依从性评定量表和世界卫生组织生活质量简表来评估药物依从性和生活质量。
277名T2DM患者参与了该研究。他们的平均年龄为50.80(±10.6)岁,155名(56%)患者对抗糖尿病药物的依从性较差,122名(44%)患者依从性良好。在对社会人口统计学因素进行调整后,多元线性回归分析发现,与未坚持用药的患者相比,坚持服用抗糖尿病药物的患者的生活质量总体平均感知得分和健康总体感知得分显著更高,β系数分别为0.36和0.34(均P = 0.000)分。
T2DM患者的药物依从性与生活质量之间存在关联。因此,有必要开展提高认识和咨询项目,随后进行定期随访,以促使患者坚持推荐的治疗和生活方式方案。